• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cognition Therapeutics Inc (NQ: CGTX )

    0.4709 -0.0012 (-0.25%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 238,738
    Open 0.4740
    Bid (Size) 0.4700 (30)
    Ask (Size) 0.4930 (3)
    Prev. Close 0.4721
    Today's Range 0.4706 - 0.4758
    52wk Range 0.3400 - 2.950
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -75.73%
    -75.73%
    1 Month
    +8.28%
    +8.28%
    3 Month
    -28.23%
    -28.23%
    6 Month
    -76.34%
    -76.34%
    1 Year
    -55.58%
    -55.58%

    More News

    Read More
    Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q2 2024
    Via InvestorPlace
    Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    Cognition Therapeutics to Report Second Quarter 2024 Financial Results
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Via InvestorPlace
    Dow Edges Lower; Ventyx Biosciences Shares Plummet
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump
    Via Benzinga
    Exposures Fossil Fuels
    Tivic Health Systems (TIVC) Stock Pops Another 39%
    Via InvestorPlace
    Cognition Therapeutics Stock Tumbles On Mixed Data From Mid-Stage Alzheimer's Study
    Via Benzinga
    Why Is NLS Pharmaceutics (NLSP) Stock Up 48% Today?
    Via InvestorPlace
    Why Is Cognition Therapeutics (CGTX) Stock Down 33% Today?
    Via InvestorPlace
    Nasdaq Gains 1%; McDonald's Posts Downbeat Results
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    Via InvestorPlace
    Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.